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Combinatorial Activity of Flavonoids with Antibiotics
Against Drug-Resistant Staphylococcus aureus
Ana Cristina Abreu,1 Sofia C. Serra,2,3 Anabela Borges,1,4 Maria Jose´ Saavedra,4
Andrew J. Mcbain,5 Anto´nio J. Salgado,2,3 and Manuel Simo˜es1
The use of resistance-modifying agents is a potential strategy that is used to prolong the effective life of
antibiotics in the face of increasing antibiotic resistance. Since certain flavonoids are potent bacterial efflux
pump inhibitors, we assessed morin, rutin, quercetin, hesperidin, and (+ )-catechin for their combined activity
with the antibiotics ciprofloxacin, tetracycline, erythromycin, oxacillin, and ampicillin against drug-resistant
strains of Staphylococcus aureus, including methicillin-resistant S. aureus. Four established methods were used
to determine the combined efficacy of each combination: microdilution checkerboard assays, time-kill deter-
minations, the Etest, and dual disc-diffusion methods. The cytotoxicity of the flavonoids was additionally
evaluated in a mouse fibroblast cell line. Quercetin and its isomer morin decreased by 3- to 16-fold the minimal
inhibitory concentration of ciprofloxacin, tetracycline, and erythromycin against some S. aureus strains. Rutin,
hesperidin, and (+ )-catechin did not promote any potentiation of antibiotics. Despite the potential cytotoxicity
of these phytochemicals at a high concentration (fibroblast IC50 of 41.8 and 67.5mg/L, respectively), quercetin
is commonly used as a supplement for several therapeutic purposes. All the methods, with exception of the
time-kill assay, presented a high degree of congruence without any apparent strain specificity.
Introduction
The discovery of most of our current arsenal of anti-microbial products has been based on the well-established
‘‘one-compound-one-drug’’ paradigm.33 However, the phar-
maceutical industry’s search for new antimicrobials has
markedly slowed in recent years and strategies to mitigate
resistance in existing drugs are urgently required, given the
substantial increase in antibiotic resistance.
Antimicrobial combinations are frequently used in clini-
cal practice to promote increased pharmacological action
or to achieve synergistic activity to treat mixed bacterial
infections in which the organisms are not susceptible to a
common agent,42,51 to overcome bacterial tolerance,34 to
prevent the emergence of drug resistance,5,65 and to mini-
mize toxicity.25 Antibiotics may also be used in combina-
tion to increase efficacy. The use of agents that inhibit
bacterial resistance mechanisms (resistance-modifying agents
[RMAs]) can be highly effective. Several inhibitors of b-
lactamases are used in combination with antibiotics: for
example, clavulanic acid is used in combination with
amoxicillin (Augmentin) and ticarcillin (Timentin), while
sulbactam is combined with ampicillin (Unasyn) and ta-
zobactam, used in combination with piperacillin (as Tazo-
cin).2 There is considerable scope for expansion of the
application of RMAs to increase the effectiveness of current
antibiotics and to avoid the emergence of resistant variants
during treatment.23,46
There has recently been a resurgence of interest in the use
of drugs based on phytochemicals.4 Plants can produce
complex mixtures of structural different products that can
interact simultaneously with several biological targets and
which can lead to enhanced efficiency.29
There are several reports of phytochemical compounds,
including flavonoids with limited antimicrobial activity that
can enhance the effect of antibiotics.2 Flavonoids are hy-
droxylated phenolics commonly found in leaves, fruits, and
flowers. The existence, number, position, and degree of sub-
stitution of hydroxyl or methyl groups on the benzene ring
provide much of the structural variation found in flavonoids9
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and they, consequently, have a diverse range of pharma-
cological properties, including anti-inflammatory, oestrogenic,
anti-allergic, antifungal, antimicrobial, and antioxidant.15,27,37
Importantly, several flavonoids were found to potentiate
some antibiotics due to a possible activity as inhibitors of
multidrug-resistant mechanisms, such as efflux pumps.2,39
Quercetin, rutin, hesperidin, and ( + )-catechin were re-
ported to have a synergistic activity when combined with
oxacillin against vancomycin-intermediate Staphylococcus
aureus (VISA).7 The goal of this work was to evaluate
whether these compounds would be able to potentiate other
antibiotics against a range of clinical isolates of antibiotic-
resistant S. aureus, including methicillin-resistant S. aureus
(MRSA) strains. Morin, the isomer of quercetin, was also
included in the tests. Ampicillin and oxacillin (b-lactams),
ciprofloxacin (fluoroquinolone), erythromycin (macrolide),
and tetracycline were selected as the resistance mechanisms
for these antibiotics are already much disseminated. To obtain
reliable conclusions about the antibiotic potentiation effects,
four distinct methods were used (microdilution broth check-
erboard, disc diffusion method, Etest, and time-kill assays).
These tests measure distinct effects of antibiotic interactions
against bacteria (growth inhibition or killing) and use dif-
ferent growth medium states (broth vs. agar).10,18,64
Materials and Methods
Bacterial strains and growth conditions
Test bacteria included MRSA (MJMC001, MJMC002,
MJMC004) and MSSA (MJMC003, MJMC009, MJMC010).
All were low-passage clinical isolates, obtained from the
Hospital Centre of Tra´s-os-Montes and Alto Douro, EPE
(Vila Real, Portugal).
Additional test strains were S. aureus SA1199B, RN4220,
and XU212, which over-express norA, msrA, and tetK, re-
spectively, and were provided by S. Gibbons (University
College London, London, United Kingdom)23,24,47,62 and
S. aureus XU212 (MRSA). S. aureus CECT 976, used in
previous studies with phytochemicals,1,57,60 was included as
a comparator. Bacteria were grown overnight at 37C and
under agitation (150 rpm) in Mueller-Hinton (MH) broth
(Merck).
Antibiotics and flavonoids
Ampicillin (AMP), ciprofloxacin (CIP), erythromycin
(ERY), oxacillin (OXA), and tetracycline (TET) were pre-
pared according to the manufacturer’s recommendations.
Morin (MOR), quercetin (QUERC), hesperidin (HESP),
rutin (RUT), and ( + )-catechin (CAT) (Fig. 1) were prepared
in dimethyl sulfoxide (DMSO, 100%). All the compounds
and reagents were obtained from Sigma.
Antibacterial susceptibility testing
Minimum inhibitory concentrations (MICs) of each agent
were determined by broth microdilution testing according to
the Clinical and Laboratory Standards Institute (CLSI)
guidelines.41 MICs were defined as the lowest concentration
of the antimicrobial compound that inhibited bacterial
growth. OD600 was measured to assess the growth of bac-
teria. Three independent experiments were performed for
each compound, and eight replicates per each concentration
were performed in each test. The highest concentration of
DMSO remaining after dilution (10%, v/v) caused no
growth inhibition (data not shown).
Antibiotic-flavonoid antibacterial effects
Antibiotic-flavonoid combinations were tested using the
broth microdilution checkerboard, disc diffusion method,
Etest, and time-kill assays. Three independent experiments
were performed for each combination and test. Based on a
new approach developed for interactions between com-
pounds that have no antimicrobial activity but that can po-
tentiate antimicrobials,3 the combinations were classified as
potentiation, additive, indifferent, or negative. Combina-
tions were classified as additive if two or more methods
presented that same interpretation of the results. Otherwise,
results obtained between the limits defined for potentiation
and negative interactions did not distinguish between addi-
tivity and indifference.
Checkerboard microdilution assay
Checkerboard assay was performed according to Bona-
pace et al.10 and Humphreys et al.31 with some modifica-
tions. The concentration of each antibiotic tested ranged
from 1/64 to 2· MIC. The flavonoids were tested at several
concentrations ranging from 10 to 1,500mg/L. The anti-
microbial solutions did not exceed 10% (v/v) of the volume
used in each well (200ml). Growth controls with DMSO at
10% (v/v) were assessed in wells not containing the che-
micals. Negative controls were performed by adding fresh
MH broth without bacteria to each combination. Incubation
was performed for 24 hours at 37C, and readings were
determined spectrophotometrically at 600 nm. For the
combinations where one of the compounds has no antimi-
crobial activity, the fractional inhibitory concentration36,53
might not be determinable. In those cases, potentiation was
defined as an antibiotic MIC reduction of 4-fold dilutions,
an additive interaction as an MIC reduction ‡2-fold and
< 4-fold dilutions, and a negative interaction as an MIC
increase of 4-fold dilutions.
Disc diffusion method
This method was a modification from the Kirby–Bauer
method and was applied in similar studies.1,57 The con-
centrations for the flavonoids were chosen according to the
checkerboard results. Each flavonoid was added to MH agar
(after autoclaved and cooled to *30C), yielding the final
concentration desired, and the medium was poured into
90mm Petri dishes. The bacterial suspensions were adjusted
to 0.5 McFarland standards and seeded over hardened MH
agar Petri dishes. Sterile blank discs (6mm diameter; Ox-
oid) were placed on the agar plate. A volume of 15 ml of
each antibiotic prepared according to the CLSI guidelines
(AMP, 10mg/disc; CIP, 5 mg/disc; ERY, 15mg/disc; TET,
30 mg/disc; and OXA, 1 mg/disc) was added to the blank
discs.14 As control, antibiotic discs were applied on simple
MH agar plates (without flavonoid). After incubation at
37C, for 24 hours, each inhibition zone diameter (IZD) was
recorded and analyzed according to CLSI guidelines.14
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According to the scheme proposed in a previous study,3 the
combination between two bioactive agents was characterized
as additive if 4£ (IZD combination - IZD most active
agent) < 6mm, and as potentiation if (IZD combination -
IZD most active agent) ‡ 6mm. The limits for negative
interactions were not defined since no negative combina-
tions were ever found.
Etest
This method was performed according to the manufactur-
er’s instructions (AB Biodisk). The concentrations for the
flavonoids were chosen according to the checkerboard results.
The bacterial inoculum and the MH agar plates were prepared
as described for the disc diffusion method, and antibiotic
Etest strips (AB Biodisk) were applied in duplicate on the
agar plates. As control, antibiotic strips were applied on
simple MH agar plates (without flavonoid). After incubation
for 24 hours at 37C, the MICs were read. For Etest, if the
MIC of antibiotic was reduced by > 3-fold dilutions, the re-
sult was considered potentiation; a reduction of ‡ 2 but < 3
was considered an additive; and an increase of threefold di-
lutions of the MIC was classified as negative.12,35,63
Time-kill assay
This method was performed according to Bonapace
et al.10 with some modifications. The antibiotics were tested
at MIC, 1/2·MIC, and 1/4 ·MIC. The concentration of
each flavonoid was chosen according to the checkerboard
results. The combinations were added to sterilized tubes and
inoculated with each isolate in a total medium volume of
10ml. The antimicrobial combinations did not exceed 10%
(v/v) of the final volume. Controls were performed with
each product separately. Colony forming units (CFU) counts
were performed after 0, 4, 8, and 24 hours of the beginning
of the incubation at 150 rpm and 37C. The limit of detec-
tion was 50 CFU/ml. Potentiation was considered as a ‡ 2-
log10 decrease in CFU/ml between the combination and its
most active constituent at the designated sample time; an ad-
ditive interaction was defined as a log10 decrease ‡ 1 and < 2
in CFU/ml; and a negative interaction was defined as a ‡ 2-
log10 increase in CFU/ml.
18,40
Cytotoxicity testing
The cytotoxicity of the flavonoids was evaluated ac-
cording to ISO/EN 10993 (part 5)32 guidelines using L929
cells (ATCC CCL 1), from an immortalized mouse lung
fibroblast cell line. Cells were grown in 175 cm2 culture
flasks using Dulbecco’s modified Eagle’s medium (DMEM;
Sigma) supplemented with 1% of penicillin and strepto-
mycin solution (Sigma) and 10% fetal bovine serum (FBS;
Biochrome). The flasks were incubated at 37C for 72 hours
in a 95% air 5% CO2 atmosphere with 100% humidity.
Then, cells were trypsinised, plated in 96-well microtiter
plates at a concentration of 1 · 104 cells per well, and left to
adhere for 24 hours at 37C in a 95% air 5% CO2 atmo-
sphere with 100% humidity. The medium in each well was
replaced by 200 ml of fresh DMEM with the flavonoids at
several concentrations. The flavonoids did not exceed 2%
(v/v) of the well final volume. Growth control was performed
by adding fresh medium without any flavonoid and the
negative control by adding DMSO at 2% (v/v). Each condi-
tion was performed in five wells and in triplicate. The plates
were incubated for 72 hours (at 37C, in a 95% air 5% CO2
atmosphere with 100% humidity). After incubation, the cell
viability was assessed using the Cell Titer 96 One solution
Cell proliferation Assay Kit (Promega). This assay involves
the bioreduction of the substrate, [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxyl-methoxy-phenyl)-2(4-sulfo-phenyl)-2H tet-
razolium] (MTS) into a brown formazan product by NADPH
or NADP produced by dehydrogenase enzymes in metaboli-
cally active cells.51 For the assay to occur, the medium with
flavonoids was removed and replaced by 200ml of a mixture
of DMEM without FBS and MTS (1:5 ratio) and incubated
for 3 hours (at 37C, in a 95% air 5% CO2 atmosphere with
FIG. 1. Chemical structures of the flavo-
noids used in this study.
FLAVONOIDS AS ANTIBIOTIC POTENTIATORS 3
100% humidity). The optical density of each well was mea-
sured at 490 nm using a plate reader (Molecular Devices).
From the dose-response curves obtained, the half maximal
inhibitory concentration (IC50) values were calculated by
probit analysis, according to Sebaugh.59
Statistical analysis
For statistical analysis, the in vitro results were analyzed by
Student’s t-test using the statistical program SPSS version
19.0 (Statistical Package for the Social Sciences). Statistical
calculations were based on a confidence level ‡ 95%
( p< 0.05) that was considered statistically significant.
Results
The classification of the S. aureus strains according to
their resistance profile was done based on the comparison of
the MICs/IZDs results of antibiotics and the susceptibility
breakpoints of the CLSI guidelines (Table 1).41 The agree-
ment between the MICs obtained by microdilution tech-
nique and Etest (within – 1-log2 dilutions) was 75% for
Table 1. MICs Obtained by Checkerboard and Etest, and IZDs Obtained by Disc-Diffusion
Method for the Antibiotics Alone Against the Staphylococcus aureus Strains Tested
MIC (mg/L) IZD (mm)
S. aureus strains Antibiotic Checkerboard Etest Disc diffusion Classification
CECT 976 CIP 1 0.064 33.3 – 0.6 S
TET 0.96 0.38 23.7 – 0.6 S
ERY 0.24 0.19 26.3 – 0.6 S
AMP 1.5 NP 36.0 – 1.0 S
OXA 0.48 NP 39.7 – 0.6 S
SA1199B CIP 128 4 13.0 – 0.0 R
XU212 TET 128 32 9.3 – 0.6 R
RN4220 ERY 256 256 NI R
MRSA MJMC001 CIP 256 > 32 NI R
TET 0.5 0.38 26.0 – 0.0 S
ERY 96 96 12.5 – 0.6 R
AMP 64 NP NI R
OXA 128 NP NI R
MRSA MJMC002 CIP 256 > 32 NI R
TET 0.5 0.38 26.0 – 0.0 S
ERY 96 96 12.0 – 0.0 R
AMP 64 NP NI R
OXA 128 NP NI R
MRSA MJMC004 CIP 256 > 32 NI R
TET 0.5 0.38 27.0 – 1.0 S
ERY 96 96 12.0 – 0.0 R
AMP 64 NP NI R
OXA 15.6 NP NI R
MSSA MJMC003 CIP 0.5 0.19 36.0 – 0.0 S
TET 2 0.38 35.0 – 1.0 S
ERY 0.5 0.19 32.3 – 0.6 S-Ia
AMP 25 NP 10.0 – 1.0 R
OXA 1 NP 23.3 – 0.6 S
MSSA MJMC009 CIP 1 0.19 36.3 – 0.6 S
TET 0.5 0.25 35.0 – 0.0 S
ERY 2 2 32.0 – 0.0 S-Ia
AMP 10 NP 10.0 – 0.0 R
OXA 1 NP 23.7 – 0.6 S
MSSA MJMC010 CIP 1 0.19 37.0 – 1.0 S
TET 0.5 0.38 37.0 – 0.0 S
ERY 0.5 0.25 32.0 – 0.0 S
AMP 10 NP 10.0 – 0.0 R
OXA 1 NP 23.7 – 0.6 S
Classification of the strains as susceptible, intermediate, or resistant according to CLSI guidelines.41
aDiscrepancies between the categorizations were considered insignificant when an isolate found intermediate by one method was
susceptible according to another, and no distinction was made in these cases. Time-Kill assays were performed only for S. aureus
SA1199B, RN4220, and XU212 since this method was conducted on the basis of those that performed best in other tests; Etest was only
directed for CIP, TET, and ERY which achieved good combinatorial results on the checkerboard and disc-diffusion method. Strains were
classified as susceptible (S), intermediate (I), and resistant (R). Data are means and SD from at least three independent experiments.
AMP, ampicillin; CIP, ciprofloxacin; ERY, erythromycin; IZD, inhibition zone diameter; MICs, minimum inhibitory concentrations;
MRSA, methicillin-resistant S. aureus; NI, no inhibition; NP, not performed; OXA, oxacillin; TET, tetracycline.
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TET, 88% for ERY, and only 38% for CIP. According to the
classifications presented by Reynolds et al.56 there was good
agreement for ERY and poor agreements for TET and CIP.
No MIC was detected for any flavonoid for concentrations
lower than 1,500mg/L (data not shown). Also, no IZD was
obtained with the flavonoids for the same amount of com-
pound (22.5 mg/disc).
Table 2 presents the results of the combinations of anti-
biotics and flavonoids obtained by checkerboard, Etest,
disc-diffusion method, and time-kill assay. Only the com-
binations that resulted in a significant modification in
comparison with antibiotics alone for, at least, one method
have been presented. The concentrations of the flavonoids
for the combination assays were chosen according to the
checkerboard results and were considered the minimal con-
centrations causing the best effects (for active compounds:
MOR, QUERC, and RUT). For CAF and THEO that had no
activity, the same concentration of the other compounds
(500mg/L) was used. Checkerboard and Etest methods re-
vealed several MIC reductions of the antibiotics, especially
Table 2. MIC Fold Reductions (for Checkerboard and Etest) and IZD Increases (for Disc-Diffusion
Method) and log10 CFU Reductions (for Time-Kill Method) Obtained with the Combination
of Antibiotics with Flavonoids (at 500mg/L)
S. aureus isolates Antib. Flav. Checkerboard Etest
Disc
diffusion Time-kill
Final
classification
CECT 976 CIP MOR 2.0 (A) NC (I) 4.4 (A) NP A (m)
QUERC 4.0 (P) 3.0 (P) 20.0 (P) NP P (T)
TET MOR 4.0 (P) 4.0 (P) 9.3 (P) NP P (T)
QUERC 4.0 (P) 12.0 (P) 24.0 (P) NP P (T)
RUT NC (I) 3.0 (P) 7.0 (P) NP P (m)
ERY MOR 2.0 (I) NC (I) 6.4 (P) NP I (m)
QUERC 4.0 (P) 2.0 (I) 14.0 (P) NP P (m)
AMP MOR 1.5 (I) NP 9.7 (P) NP —
SA1199B CIP MOR NC (I) 3.0 (P) 13.7 (P) - 1.6 (I) P (m)
QUERC 4.0 (P) 3.0 (P) 18.9 (P) - 1.2 (I) P (T)
XU212 TET MOR NC (I) NC (I) NC (I) 1.2 (I) I (T)
QUERC NC (I) NC (I) NC (I) 2.3 (P) I (T)
MRSA MJMC001 TET MOR 4.0 (P) 3.0 (P) 6.0 (P) NP P (T)
QUERC 8.0 (P) 8.0 (P) 6.1 (P) NP P (T)
MRSA MJMC002 TET MOR 4.0 (P) 6.0 (P) 9.0 (P) NP P (T)
QUERC 8.0 (P) 6.0 (P) 18.0 (P) NP P (T)
RUT NC (I) NC (I) 8.3 (P) NP I (m)
MRSA MJMC004 TET MOR 4.0 (P) 4.0 (P) 9.0 (P) NP P (T)
QUERC 8.0 (P) 8.0 (P) 6.0 (P) NP P (T)
MSSA MJMC003 CIP MOR 2.0 (I) 6.0 (P) 8.3 (P) NP P (m)
QUERC 2.0 (I) NC (I) 15.0 (P) NP I (m)
TET MOR 4.0 (P) 12.0 (P) 10.7 (P) NP P (T)
QUERC 2.0 (A) 8.0 (P) 4.3 (A) NP A (m)
ERY MOR 2.0 (A) 2.0 (A) 15.0 (P) NP A (m)
QUERC NC (I) NC (I) 5.0 (I) NP I (T)
MSSA MJMC009 CIP MOR NC (I) 6.0 (P) 9.7 (P) NP P (m)
QUERC NC (I) NC (I) 6.3 (P) NP I (m)
TET MOR 8.0 (P) 8.0 (P) 6.0 (P) NP P (T)
QUERC 4.0 (P) 3.0 (P) 11.7 (P) NP P (T)
ERY MOR 2.0 (I) 16.0 (P) 18.1 (P) NP P (m)
QUERC NC (I) 3.0 (P) 16.3 (P) NP P (m)
MSSA MJMC010 CIP MOR 2.0 (I) 16.0 (P) 6.0 (P) NP P (m)
TET MOR 8.0 (P) 8.0 (P) 10.3 (P) NP P (T)
QUERC 2.0 (I) 8.0 (P) 6.0 (P) NP P (m)
ERY MOR 2.0 (I) 3.0 (P) 10.1 (P) NP P (m)
QUERC 2.0 (A) 2.0 (A) 13.0 (P) NP A (m)
AMP QUERC NC (I) NP 3.2 (I) NP I (—)
Only the combinations that were significantly different from the antibiotic control in, at least, one method were represented. An additive
interaction was only accepted and distinguished from indifference when two or more methods indicated that same categorical result. Time-
Kill assays were performed only for S. aureus SA1199B, RN4220, and XU212 since this method was conducted on the basis of those that
performed best in other tests; Etest was only directed for CIP, TET, and ERY, which achieved good combinatorial results on the
checkerboard and disc-diffusion method. Classifications of the combinations as potentiation (P), additive (A), or indifferent (I) are given in
parentheses. The final classification considers the results of checkerboard, Etest, and disc diffusion method. Total agreement (T): All
methods have the same interpretative category; minor disagreement (m): one method displays disagreement results. Data are means and SD
from at least three independent experiments.
CAT, ( + )-catechin; CFU, colony forming units; HESP, hesperidin; MOR, morin; NC, no change; QUERC, quercetin; RUT, rutin.
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in the presence of MOR and QUERC (at 500mg/L). The
same behavior was observed by disc-diffusion method,
where the higher IZD increases were obtained, especially
with MOR and QUERC. No MIC increase or IZD decrease
was obtained for antibiotics with the addition of flavonoids
( p > 0.05).
Figure 2 presents the log10 CFU/ml results versus time for
each combination. Time-kill assays were performed only for
S. aureus SA1199B, RN4220, and XU212 since this method
was performed on combinations selected on the basis of
their performance, assessed by the other three tests. No log10
CFU reduction was observed with the flavonoids alone for
the concentrations tested when compared with the growth
control ( p> 0.05, data not shown). Log10 CFU/ml increases
were obtained for S. aureus SA1199B when CIP (at 1/2
MIC) was combined with MOR and QUERC, compared
with CIP alone (1.6 and 1.2 log10 increases of CFU/ml,
respectively). The other methods provided potentiating ef-
fects for these combinations (Table 2). For S. aureus
XU212, TET combined with MOR and QUERC caused a
1.8 and 1.7 log10 CFU/ml reduction, respectively, when
compared with TET (at 1/4 MIC) and 1.2 and 2.6 log10
CFU/ml reduction, respectively, compared with TET (at 1/2
MIC). However, indifferent results were obtained for these
combinations with the other three methods (Table 2). For
S. aureus RN4220, time-kill assay and the other methods
provided indifferent results.
The combinations tested with the four methods were
classified as potentiation, additive, or indifferent as previ-
ously described (Table 2). No negative effects were observed.
Considering the total agreement and minor disagreement
cases (for checkerboard, Etest, and disc-diffusion method;
Table 2), potentiation was found for 24 of 190 combinatorial
cases (12.6%) and additive interactions only for 4 of 190
combinations (2.1%). The majority of the combinations
(84.2%) were indifferent.
Potentiation was obtained for the combination of MOR
with: CIP against SA1199B and MSSA strains (3/3), TET
against CECT 976, MRSA (3/3), and MSSA strains (3/3),
and ERY against MSSA (2/3); for the combination of
QUERC with: CIP against CECT 976, SA1199B, and
MSSA (1/3), TET against CECT 976, MRSA (3/3), and
MSSA (2/3) strains, and ERY against CECT 976 and MSSA
(1/3); and for the combination of RUT with TET against
FIG. 2. Log10 CFU/ml
obtained for 24 hours time-
kill assay for: CIP (1/4
MIC and 1/2 MIC) +
flavonoids (500mg/L)
against Staphylococcus
aureus SA1199B (A);
TET (1/4 MIC and 1/2
MIC) + flavonoids against
S. aureus XU212 (B); and
ERY (1/4 MIC and 1/2
MIC) + flavonoids against
S. aureus RN4220 (C).
Growth control (without
antibiotic treatment) (A),
antibiotic control (-),
MOR (:), QUERC (,),
RUT (· ), HESP (C), CAT
(:). The means – SD for at
least three separate experi-
ments are illustrated. Data
are means and SD from at
least three independent ex-
periments. No significant
CFU reduction was ob-
tained with flavonoids
alone ( p > 0.05). CAT,
( + )-catechin; CFU, colo-
ny-forming unit;
CIP, ciprofloxacin; ERY,
erythromycin; HESP, hes-
peridin; MICs, minimum
inhibitory concentrations;
MOR, morin; QUERC,
quercetin; RUT, rutin; SD,
standard deviation; TET,
tetracycline.
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CECT 976. No additive or potentiating effects were ob-
tained with CAT or HESP. Furthermore, no flavonoid po-
tentiated the activity of either b-lactam (ampicillin and
oxacillin).
Agreement between checkerboard, Etest, and disc-diffusion
method was 85%. Agreement between time-kill assay and
the other three methods for S. aureus SA1199B, XU212, and
RN4220 was 80%. However, time-kill assay usually failed
to agree with the other methods for the most promising
combinations (with MOR and QUERC) against S. aureus
SA1199B and XU212. Agreement was observed in 108 of
120 cases (90%) between checkerboard and Etest, in 111 of
120 cases (92.5%) between Etest and disc-diffusion method,
and in 174 of 190 cases (91.6%) between disc-diffusion
method and checkerboard. Minor disagreements for check-
erboard, Etest, and disc-diffusion method were obtained for
18 of 120 cases, respectively (15.0%). No major disagree-
ments were obtained between these three methods.
Cytotoxicity tests of the flavonoids were performed using
the MTS viability assay of L929 cells. The DMSO (2%) was
not toxic for cells (data not shown). From the dose-response
curves obtained, IC50 values were calculated by probit anal-
ysis. QUERC, MOR, and HESP presented low values of IC50
(41.8, 67.5, and 50.4mg/L, respectively) after 72 hours of
incubation with L929 cells. CAT had an IC50 of 302.5mg/L,
and RUT showed the highest value (1267.5mg/L).
Discussion
In this study, various combinations of selected flavonoids
and antibiotics were tested for their antibacterial potency
using four different methods. This strategy maximized the
likelihood of detecting potentiating combinations. Potentiat-
ing and additive interactions were found in 24 and 4 of 190
combinatorial cases (12.6% and 2.1%), respectively, and
mainly for combinations involving MOR and QUERC. Both
MOR and QUERC increased the activity of CIP and TET
against S. aureus CECT 976; of CIP against SA1199B; and of
TET against all MRSA and MSSA strains. In addition, some
potentiation/additive interactions were found with MOR and
QUERC combined with ERY. RUT only caused potentiation
when combined with TET against S. aureus CECT 976.
While some potentiating results were found on some S. au-
reus strains, this was not observed for others.
Experimentation on drug combinations can lead to oppo-
site conclusions by different methodologies since they use
different endpoints (inhibition or killing) and medium state
(broth vs. agar).10,18,64 There was a high degree of agreement
between checkerboard, Etest, and disc-diffusion methods
(85%) but generally lower agreement for time-kill assays,
probably because this is a test for bactericidal activity, con-
trarily to the others. Other researchers have already developed
some comparisons on the agreement between these methods,
which varies a lot between studies.3,13,38,44,48,64
QUERC is the most abundant flavonol found in the hu-
man diet.17 MOR is the isomer of QUERC and it has also
been found to possess antibacterial activity. RUT is the
glycosidic form of QUERC.6 Reports on the antibacterial
activity of these flavonoids are conflicting, especially re-
garding their MICs, probably owing to inter- and intra-assay
variation in susceptibility testing or due to the difference in
genetic variation of the strain.7,16,30,54,55 Both MOR and
QUERC (500mg/disc) were reported to inhibit the growth of
S. aureus, CAT (500mg/disc) only had a slightly activity,
and RUT (500mg/disc) had no antimicrobial activity.55 The
concentration of 500mg/disc is, however, much higher than
the highest used in this study, 22.5 mg/disc. In another study,
the MIC of QUERC against S. aureus was found to be
80mg/L.54 QUERC (15mg/L) was found to exert antibac-
terial activity against S. aureus, including MRSA, and to
potentiate the activity of erythromycin, oxacillin, ampicillin,
vancomycin, and gentamicin against MRSA.30 Other in-
vestigations showed that 87.3% of the combinations be-
tween eight flavonoids (including CAT, HESP, QUERC,
and RUT) and OXA were synergistic against VISA.7
However, in this study, no synergism was obtained with
OXA against the tested S. aureus strains. Eumkeb et al.20
also demonstrated that QUERC, galangin, and baicalein
exhibited the potential to reverse bacterial resistance to b-
lactam antibiotics against penicillin-resistant S. aureus ap-
parently due to interaction with penicillinase, cytoplasmic
membrane damage, inhibition of protein synthesis, and
changes in the PBP2a.
Other studies with polyphenolic compounds also reported
potentiating activities with some antibiotics against different
bacterial strains. These studies were already reviewed
elsewhere.2,22 Besides, many of these compounds are re-
ported to have common mechanisms of action by inhibition
of efflux pumps, or PBP2a, or increasing the membrane
permeability, their activity may significantly vary when in-
teracting with other biomolecules. Also, considering that
these studies used different bacterial strains, antibiotics, and
methods, it can be difficult to compare results on the basis of
a structure-activity relationship.
In this study, the only potentiation of an antibiotic against
a strain resistant to that antibiotic was observed for
SA1199B with the combination of MOR/QUERC and CIP.
In the other combinations, potentiation occurred only with
strains that were susceptible to the antibiotics. Therefore,
with the exception of the first situation, which may be due to
efflux pump inhibition, these activities are, in general,
probably not related to RMA. In fact, several studies have
examined the potential of QUERC to inhibit various bac-
terial enzymes, explaining why this molecule has such a
diverse applicability (including anti-tumor therapy, neuro-
protection, cardiovascular disease profylaxis, inflammation,
diabetes mellitus, infection, etc).21,26,58 However, it is clear
that further research is necessary to understand MOR/
QUERC potentiation of CIP, TET, and ERY. One of the
proposed mechanisms of action of QUERC was the inhibi-
tion of gyrases through two different mechanisms based
either on interaction with DNA or with ATP binding site of
gyrase.52 Since CIP also functions by inhibiting DNA gyr-
ase, the presence of a second compound with the same target
could inhibit or potentiate its activity. In fact, in this study,
potentiation of CIP by QUERC was found. To our knowl-
edge, data on MOR as antimicrobial and RMA are scarce or
even inexistent.
It has been suggested that flavonoids are likely to have
limited toxicity, because they are widely distributed in ed-
ible plants and beverages and have previously been used in
traditional medicine.11 Indeed, in the United States, the
daily dietary intake of mixed flavonoids is estimated to be in
the range of 500–1,000mg.61 QUERC has also been used as
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a dietary supplement (250–500mg thrice per day) for ther-
apeutic purposes. However, in this study, QUERC presented
low values of IC50 after 72 hours of incubation with L929
cells (41.8mg/L). This value is in accordance with some
other reports. Ngomuo and Jones43 carried out the cytotoxic
effects of QUERC and other compounds, and they reported
inhibition of cell growth by 50% after 48 hours of incuba-
tion for QUERC at 24mg/L for Chinese hamster ovary cells,
36mg/L for mouse fibroblast cells (3T3), and 21mg/L for
normal rat kidney cells. Pawlikowska-Pawlega and Ga-
wron50 reported that QUERC caused partial growth inhibi-
tion of mouse fibroblast cells (NCTC) when used at 10mg/
L, and almost complete growth inhibition when applied at
50mg/L. However, based on the information provided by
Quercegen Pharmaceutics regarding toxicological safety
studies (pers. comm.), human clinical studies corroborating
epidemiological studies, human pharmacokinetic studies, as
well as other information available to Food and Drug Ad-
ministration (FDA), quercetin received generally regarded
as safe (GRAS) status for its intended use as an ingredient in
beverages, grain products and pastas, processed fruits and
fruit juices, and soft candies at levels till 500mg per serving.
FDA has not, however, made its own determination re-
garding the GRAS status of the subject use of quercetin.
There are tens of reports in the literature regarding the
potential benefits of QUERC for various applications, with
various purported modes of action, while others refer to
toxicity issues.21,26,58 Although QUERC has tested positive
for mutagenicity and genotoxicity in vitro in some reports,
other in vitro studies suggest that QUERC is protective
against genotoxicants and regarded as antimutagenic.45 The
implications of these conflicting findings in an assessment of
human safety have not been established.28 Therefore, the
mechanisms underlying its biological effects remain obscure
and understanding how QUERC causes either protection or
cell death in the same model is a research priority.49
Considering the considerable number of studies reporting
the potentially beneficial effects of QUERC on health, little
is known about its bioavailability.19 Currently, a number of
studies have been carried out in both animals and humans.
However, in vivo data on the disposition, absorption, bio-
availability, and metabolism of QUERC are scarce and
contradictory. The low bioavailability of flavonoids has
been a concern. However, it can be improved by using food
matrix components or particular delivery forms.8 Harwood
et al.28 reviewed important studies about bioavailability,
distribution, excretion of QUERC, and so on.
The clinical benefits and the effective synergism of these
combinations have to be determined in vivo through care-
fully designed pharmacokinetic studies in animals. De-
termination of synergy or potentiation in vitro might not be
reflected in vivo because of the potential failure to achieve
synergistic levels of drugs in the desired tissue, the differ-
ences in plasma protein binding, and the drug metabolism.33
The modification and optimization of the compounds based
on the structure-activity relationship, in a way that the in-
trinsic pharmacological effect of each one is completely
suppressed and only the potentiating effect with the antibi-
otics is present, is also a further step of research.
In conclusion, this study aimed at testing the combination
of five selected flavonoids with common antibiotics searching
for potentiating activities. MOR and QUERC were high-
lighted as antibiotic potentiators. However, the toxicity of
these compounds may be a barrier. More information about
pharmacokinetics of both compounds would be necessary.
Their possible use in combination for surface coating can be a
potential immediate application. Despite measuring different
end-points, the use of the four methods enabled a solid
conclusion to be reached about the results and also permitted
to overcome and circumvent the limitations of each method.
Disc-diffusion method is raised as an excellent strategy, be-
cause it is very easy to perform, has good agreement results
with the other methods, and is low-priced.
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